Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Paramount Biocapital Asset Management
AddedFeb 19, 2024
UpdatedJun 28, 2026
Paramount Biocapital Asset Management

Paramount Biocapital Asset Management

Operating

Paramount Biocapital, a pharmaceutical development firm, manages hedge and private equity investments.

Location
New York City, NY, US
Founded
2008
Firm
Compare
Portfolio
Employees
Website

Paramount Biocapital Asset Management focuses on pharmaceutical development and manages hedge and private equity investments. The firm typically engages in post-IPO equity rounds, providing substantial financial backing to companies within the pharmaceutical sector.

Notable portfolio companies include Alaunos Therapeutics, which has raised $37 million, and Cel-Sci, with $4.4 million in funding. Paramount Biocapital's investment philosophy centers on leveraging their expertise in pharmaceutical development to drive growth and innovation in their portfolio companies.

Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments2
Current Portfolio Count2
Total Portfolio Exits0

Top Investment Stages

Post Ipo Equity2 (100.0%)

Stage Mix

Post Ipo Equity 100%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Cel-Sci logo

Cel-Sci

Alaunos Therapeutics logo

Alaunos Therapeutics

Similar Investment Firms

Petrichor Healthcare Capital Management logo

Petrichor Healthcare Capital Management

petrichorcap.com

Fairmount Funds Management logo

Fairmount Funds Management

fairmountfunds.com

Altium Capital logo

Altium Capital

altiumcap.com

PBM Capital Group logo

PBM Capital Group

pbmcap.com

PFM Health Sciences logo

PFM Health Sciences

Princeton Biopharma Capital Partners logo

Princeton Biopharma Capital Partners

princetonbcp.com

Nantahala Capital Management logo

Nantahala Capital Management

BioImpact Capital logo

BioImpact Capital

Mirae Asset Capital Life Science logo

Mirae Asset Capital Life Science

Amicus Capital Partners logo

Amicus Capital Partners

MPM Capital logo

MPM Capital

mpmbioimpact.com

Health Innovation Capital logo

Health Innovation Capital

Brio Capital Management logo

Brio Capital Management

Pamplona Capital Management logo

Pamplona Capital Management

pamplonafunds.com

Bain Capital Life Sciences logo

Bain Capital Life Sciences

baincapital.com

Paramount Biocapital Asset Management - Classification

Also Known As
  • Paramount Biocapital Asset Management Inc
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
Show 5 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified